X

Trial Profile

Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
Indications Thrombotic thrombocytopenic purpura
Focus Therapeutic Use
Acronyms REACT-2020

Most Recent Events

09 Dec 2024 Planned End Date changed from 1 Mar 2025 to 12 Dec 2034.
09 Dec 2024 Planned primary completion date changed from 1 Oct 2024 to 12 Dec 2034.
22 Dec 2022 Results evaluating patient selection, tailoring of therapy duration, obstacles in prescribing caplacizumab in iTTP, effect on adjunct treatment, and outcomes in the real-world setting,published in the Journal of Thrombosis and Haemostasis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com